Drugs / CDK-002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04592484 | Sep 2020 → Aug 2022 | neoplasm | Codiak BioSciences | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CDK-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04592484 ↗ |
| Known as | exoSTING | “A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors” NCT04592484 ↗ |